Characterization of a novel oil-in-water emulsion adjuvant for swine influenza virus and Mycoplasma hyopneumoniae vaccines. Issue 25 (9th June 2015)

• Record Type: Journal Article
• Authors: Galliher-Beckley, A.; Pappan, L.K.; Madera, Rachel; Burakova, Y.; Waters, A.; Nickles, M.; Li, X.; Nietfeld, J.; Schlup, J.R.; Zhong, Q.; McVey, S.; Dritz, S.S.; Shi, J.
• Is Part Of: Vaccine. Volume 33:Issue 25(2015)
• Page Start: 2903
• Page End: 2908
• Publication Date: 2015-06-09
• Subjects: Adjuvant -- Oil-in-water emulsion -- Swine influenza virus -- Mycoplasma -- Vaccine; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2015.04.065
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Vaccines consisting of subunit or inactivated bacteria/virus and potent adjuvants are widely used to control and prevent infectious diseases. Because inactivated and subunit antigens are often less antigenic than live microbes, a growing need exists for the development of new and improved vaccine adjuvants that can elicit rapid and long-lasting immunity. Here we describe the development and characterization of a novel oil-in-water emulsion, OW-14. OW-14 contains low-cost plant-based emulsifiers and was added to antigen at a ratio of 1:3 with simple hand mixing. OW-14 was stable for prolonged periods of time at temperatures ranging from 4 to 40 °C and could be sterilized by autoclaving. Our results showed that OW-14 adjuvanted inactivated swine influenza viruses (SIV; H3N2 and H1N1) and Mycoplasma hyopneumoniae ( M. hyo ) vaccines could be safely administered to piglets in two doses, three weeks apart. Injection sites were monitored and no adverse reactions were observed. Vaccinated pigs developed high and prolonged antibody titers to both SIV and M. hyo . Interestingly, antibody titers were either comparable or greater than those produced by commercially available FluSure (SIV) or RespiSure ( M. hyo ) vaccines. We also found that OW-14 can induce high antibody responses in pigs that were vaccinated with a decreased antigen dose. This study provides direct evidence that we have developed an easy-to-use and low-cost emulsion that can act as a powerful adjuvant in two common types of swine vaccines.